why choose us

First received: September 12, 2022

Clinical Trial: A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications

Study Status: Completed

Recruit Status: RECRUITING

Condition: Movement Disorders

Study Type: OBSERVATIONAL


Official Title: A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Se

Brief Summary: This registry is a prospective, multicenter, international, single arm, observational post-approval registry with follow-up at 3, 6, and 12 months, and annually for 5 years.The proposed registry will enroll 60 subjects and will be conducted at approximately 10 centers worldwide.

Read more